---
type: "Topics"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/topics/39995078.md"
description: "$Sarepta醫療(SRPT.US) | 薩雷普塔：H.C. Wainwright 重申賣出評級，維持目標價在$5分析師認為，新的羅氏研究帶來了日益增加的有效性風險，其核心美國 ELEVIDYS 特許經營權的上行空間有限，下行風險顯著。來源：Hardik Shah"
datetime: "2026-04-17T11:17:30.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39995078.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39995078.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39995078.md)
author: "[Hardik Shah](https://longbridge.com/zh-HK/profiles/27423834.md)"
---

# $Sarepta醫療(SRPT.US) | 薩雷普塔：H.C. Wainwright 重申賣出評級，…


### 相關股票

- [SRPT.US](https://longbridge.com/zh-HK/quote/SRPT.US.md)
- [RHHBY.US](https://longbridge.com/zh-HK/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/zh-HK/quote/RHHVF.US.md)